CY1112229T1 - Αντισωματα κατευθυνομενα εναντι οξειδωμενης απολιποπρωτεϊνης β - Google Patents
Αντισωματα κατευθυνομενα εναντι οξειδωμενης απολιποπρωτεϊνης βInfo
- Publication number
- CY1112229T1 CY1112229T1 CY20111100305T CY111100305T CY1112229T1 CY 1112229 T1 CY1112229 T1 CY 1112229T1 CY 20111100305 T CY20111100305 T CY 20111100305T CY 111100305 T CY111100305 T CY 111100305T CY 1112229 T1 CY1112229 T1 CY 1112229T1
- Authority
- CY
- Cyprus
- Prior art keywords
- oxidated
- protein
- self
- guided against
- passive immunization
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Abstract
Η παρούσα εφεύρεση αφορά παθητική ανοσοποίηση για θεραπεία ή αποτροπή αθηροσκλήρωσης χρησιμοποιώντας ανασυνδυασμένο ανθρώπινο αντίσωμα κατευθυνόμενο έναντι τουλάχιστον ενός οξειδωμένου θραύσματος απολιποπρωτεΐνης Β στην βιομηχανική κατασκευή μιας φαρμακευτικής σύνθεσης για θεραπευτική ή προφυλακτική αγωγή αθηροσκλήρωσης με την βοήθεια παθητικής ανοσοποίησης, καθώς επίσης μέθοδο για παρασκευή τέτοιων αντισωμάτων και μέθοδο για την θεραπεία θηλαστικού, κατά προτίμηση ανθρώπου, χρησιμοποιώντας ένα τέτοιο αντίσωμα για να παρέχεται παθητική ανοσοποίηση.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0202959A SE0202959D0 (sv) | 2002-10-04 | 2002-10-04 | Peptide-Base passive immunization therapy for treatment of atherosclerosis |
SE0302312A SE0302312D0 (sv) | 2002-10-04 | 2003-08-27 | Peptide-based passive immunization therapy for treatment of atherosclerosis |
EP03748843A EP1545609B1 (en) | 2002-10-04 | 2003-10-06 | Antibodies directed against oxidised apolipoprotein B |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1112229T1 true CY1112229T1 (el) | 2015-12-09 |
Family
ID=28677712
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20111100305T CY1112229T1 (el) | 2002-10-04 | 2011-03-21 | Αντισωματα κατευθυνομενα εναντι οξειδωμενης απολιποπρωτεϊνης β |
Country Status (20)
Country | Link |
---|---|
US (6) | US7468183B2 (el) |
EP (3) | EP2359848A1 (el) |
JP (5) | JP2006506450A (el) |
CN (3) | CN102319429A (el) |
AT (1) | ATE498407T1 (el) |
AU (2) | AU2003263712A1 (el) |
BR (1) | BR0315042A (el) |
CY (1) | CY1112229T1 (el) |
DE (1) | DE60336068D1 (el) |
DK (1) | DK1545609T3 (el) |
EE (1) | EE200500012A (el) |
ES (1) | ES2387423T3 (el) |
HK (1) | HK1087018A1 (el) |
PL (1) | PL376964A1 (el) |
PT (1) | PT1545609E (el) |
RU (2) | RU2322260C2 (el) |
SE (1) | SE0302312D0 (el) |
SI (1) | SI1545609T1 (el) |
TW (2) | TW200835517A (el) |
WO (1) | WO2004030698A1 (el) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10353175A1 (de) | 2003-11-14 | 2005-06-16 | Müller-Hermelink, Hans Konrad, Prof. Dr. | Humaner monoklonaler Antikörper mit fettsenkender Wirkung |
EP1531162A1 (en) * | 2003-11-14 | 2005-05-18 | Heinz Vollmers | Adenocarcinoma specific antibody SAM-6, and uses thereof |
GB0517878D0 (en) * | 2005-09-02 | 2005-10-12 | Bioinvent Int Ab | Immunotherapeutic treatment |
WO2009083225A2 (en) * | 2007-12-28 | 2009-07-09 | Biolnvent International Ab | Formulation |
JP5913980B2 (ja) | 2008-10-14 | 2016-05-11 | ジェネンテック, インコーポレイテッド | 免疫グロブリン変異体及びその用途 |
EP2393836A4 (en) * | 2009-02-09 | 2012-09-26 | Patrys Ltd | SAM-6 VARIANTS, TARGET AND USE PROCESS |
WO2010107380A1 (en) * | 2009-03-17 | 2010-09-23 | Forskarpatent I Syd Ab | Immunomodulatory methods and systems for treatment and/or prevention of atherosclerosis and related proteins, peptides and compositions |
CU23736A1 (es) | 2009-05-04 | 2011-11-15 | Centro Inmunologia Molecular | Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso |
US20110256134A1 (en) * | 2009-08-28 | 2011-10-20 | Stuart Bunting | Methods of treatment using anti-oxidized ldl antibodies |
US9125850B2 (en) | 2009-11-14 | 2015-09-08 | Cardio Vax, Llc | Immunomodulatory methods and systems for treatment and/or prevention of atherosclerosis |
AU2011325946A1 (en) | 2010-11-12 | 2013-05-30 | Cedars-Sinai Medical Center | Immunomodulatory methods and systems for treatment and/or prevention of aneurysms |
WO2012074725A2 (en) | 2010-11-12 | 2012-06-07 | Cedars-Sinai Medical Center | Immunomodulatory methods and systems for treatment and/or prevention of hypertension |
SG11201408491SA (en) * | 2012-06-21 | 2015-01-29 | Univ Indiana Res & Tech Corp | Analogs of glucagon exhibiting gip receptor activity |
US10434141B2 (en) | 2016-05-31 | 2019-10-08 | Abcentra, Llc | Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody |
US10858422B2 (en) | 2016-05-31 | 2020-12-08 | Abcentra, Llc | Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody |
CN110950952A (zh) * | 2019-12-17 | 2020-04-03 | 东莞市东阳光生物药研发有限公司 | 制备抗体的方法 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4970144A (en) * | 1984-12-31 | 1990-11-13 | International Genetic Engineering | Peptide fragments of human apolipoprotein, type-specific antibodies and methods of use |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5972890A (en) * | 1988-05-02 | 1999-10-26 | New England Deaconess Hospital Corporation | Synthetic peptides for arterial imaging |
US5196324A (en) * | 1989-12-15 | 1993-03-23 | Eli Lilly And Company | Monoclonal antibodies reactive with a human atheroma associated antigen |
WO1994000592A1 (en) * | 1992-06-26 | 1994-01-06 | Exocell, Inc. | Monoclonal antibodies against glycated low density lipoprotein |
US5678548A (en) | 1995-07-20 | 1997-10-21 | The United States Of America As Represented By The Department Of Health And Human Services | System and method for performing in vivo imaging and oxymetry and FT microscopy by pulsed radiofrequency electron paramagnetic resonance |
CN1206421A (zh) * | 1995-11-01 | 1999-01-27 | 科斯药品公司 | 载脂蛋白e2和阿尔采默氏病的治疗 |
KR0185334B1 (ko) * | 1995-11-02 | 1999-04-01 | 김은영 | 인간 혈장 아포지단백질 비-100에 결합하는 생쥐 항체를 암호하는 씨디엔에이 |
GB9620153D0 (en) | 1996-09-27 | 1996-11-13 | Univ Strathclyde | Non-naturally occurring lipoprotein particle |
GB9701425D0 (en) | 1997-01-24 | 1997-03-12 | Bioinvent Int Ab | A method for in vitro molecular evolution of protein function |
GB9705831D0 (en) * | 1997-03-20 | 1997-05-07 | Univ Leicester | Oxidised ldl |
US6635623B1 (en) | 1997-06-13 | 2003-10-21 | Baylor College Of Medicine | Lipoproteins as nucleic acid vectors |
US6225070B1 (en) * | 1997-08-07 | 2001-05-01 | The Regents Of The University Of California | Antibodies to oxidation-specific epitopes on lipoprotein and methods for their use in detecting, monitoring and inhibiting the growth of atheroma |
DE69827805T2 (de) * | 1997-08-12 | 2005-12-15 | Leadd B.V. | Verfahren und vorrichtung zur bestimmung des transformationspotentials von verbindungen. |
US6156315A (en) | 1997-10-10 | 2000-12-05 | The Trustees Of Columbia University In The City Of New York | Method for inhibiting the binding of low density lipoprotein to blood vessel matrix |
AU5200699A (en) | 1998-07-13 | 2000-02-01 | University Of Otago | Inhibition of lipoprotein formation |
WO2001032070A2 (en) * | 1999-10-26 | 2001-05-10 | The Regents Of The University Of California | Reagents and methods for diagnosing, imaging and treating atherosclerotic disease |
CA2401755A1 (en) * | 2000-03-03 | 2001-09-07 | Smithkline Beecham Biologicals S.A. | Vaccine for the treatment of artherosclerosis |
SE0103754L (sv) * | 2001-04-05 | 2002-10-06 | Forskarpatent I Syd Ab | Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid |
US20030105003A1 (en) * | 2001-04-05 | 2003-06-05 | Jan Nilsson | Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
JP4159300B2 (ja) | 2001-07-05 | 2008-10-01 | 株式会社リコー | 画像定着装置及び画像形成装置 |
-
2003
- 2003-08-27 SE SE0302312A patent/SE0302312D0/xx unknown
- 2003-09-22 AU AU2003263712A patent/AU2003263712A1/en not_active Abandoned
- 2003-09-22 WO PCT/SE2003/001469 patent/WO2004030698A1/en not_active Application Discontinuation
- 2003-09-25 TW TW097111600A patent/TW200835517A/zh unknown
- 2003-09-25 TW TW092126462A patent/TWI299666B/zh not_active IP Right Cessation
- 2003-10-03 US US10/679,032 patent/US7468183B2/en not_active Expired - Lifetime
- 2003-10-06 BR BR0315042-9A patent/BR0315042A/pt not_active IP Right Cessation
- 2003-10-06 JP JP2005500961A patent/JP2006506450A/ja active Pending
- 2003-10-06 CN CN2010101282346A patent/CN102319429A/zh active Pending
- 2003-10-06 SI SI200331982T patent/SI1545609T1/sl unknown
- 2003-10-06 PT PT03748843T patent/PT1545609E/pt unknown
- 2003-10-06 PL PL376964A patent/PL376964A1/pl not_active Application Discontinuation
- 2003-10-06 EP EP10075393A patent/EP2359848A1/en not_active Withdrawn
- 2003-10-06 EE EEP200500012A patent/EE200500012A/xx unknown
- 2003-10-06 DE DE60336068T patent/DE60336068D1/de not_active Expired - Lifetime
- 2003-10-06 ES ES03748843T patent/ES2387423T3/es not_active Expired - Lifetime
- 2003-10-06 EP EP10075394A patent/EP2361633A1/en not_active Withdrawn
- 2003-10-06 CN CN2010101282350A patent/CN102172400A/zh active Pending
- 2003-10-06 CN CN2011102300859A patent/CN102380097A/zh active Pending
- 2003-10-06 RU RU2005113235/15A patent/RU2322260C2/ru not_active IP Right Cessation
- 2003-10-06 AT AT03748843T patent/ATE498407T1/de active
- 2003-10-06 EP EP03748843A patent/EP1545609B1/en not_active Expired - Lifetime
- 2003-10-06 DK DK03748843.4T patent/DK1545609T3/da active
-
2005
- 2005-12-30 US US11/323,123 patent/US7601353B2/en not_active Expired - Fee Related
-
2006
- 2006-06-23 HK HK06107155.0A patent/HK1087018A1/xx not_active IP Right Cessation
- 2006-12-19 US US11/612,591 patent/US20080008702A1/en not_active Abandoned
-
2007
- 2007-10-30 US US11/928,221 patent/US7521046B2/en not_active Expired - Fee Related
- 2007-11-02 RU RU2007140978/15A patent/RU2007140978A/ru not_active Application Discontinuation
-
2008
- 2008-10-27 US US12/258,745 patent/US8114966B2/en not_active Expired - Fee Related
-
2009
- 2009-03-31 AU AU2009201260A patent/AU2009201260B2/en not_active Ceased
-
2010
- 2010-01-07 JP JP2010001795A patent/JP2010104374A/ja active Pending
- 2010-01-07 JP JP2010001794A patent/JP2010136721A/ja active Pending
- 2010-01-07 JP JP2010001796A patent/JP2010104375A/ja active Pending
- 2010-06-22 JP JP2010141960A patent/JP2010222378A/ja active Pending
-
2011
- 2011-03-21 CY CY20111100305T patent/CY1112229T1/el unknown
- 2011-10-13 US US13/272,297 patent/US20120070426A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1112229T1 (el) | Αντισωματα κατευθυνομενα εναντι οξειδωμενης απολιποπρωτεϊνης β | |
ATE470676T1 (de) | Anti-vegf-2 antikörper | |
CY1109525T1 (el) | ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΑ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ErbB2 ΚΑΙ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΜΕ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ErbB2 | |
BR0315161A (pt) | Anticorpo isolado, polinicleotìdeo isolado, vetor, célula hospedeira, método de produzir um anticorpo, e, composição | |
LU93274I2 (fr) | Elotuzumab | |
NI200600098A (es) | Anticuerpos que se unen al receptor de interleuquina-4 | |
DE60134962D1 (de) | Anti-ccr4 antikörper und fragmente davon | |
ATE423571T1 (de) | Verwendung von bispezifischen antikörpern gegen einen aktivierenden rezeptor fcepsilonri und gegen einen inhibierenden rezeptor ox2ra (cd200ra) zur regulierung der immunantworten | |
DK1212422T3 (da) | Humane CTLA-4-antistoffer og anvendelserne deraf | |
PL400308A1 (pl) | Terapia immunizacyjna w oparciu o peptydy do leczenia miazdzycy oraz w oparciu o peptydy do okreslania odpowiedzi odpornosci przeciwko utlenionym lipoproteinom o niskiej gestosci | |
CY1112425T1 (el) | Αντισωματα αντι-ngf για την θεραπευτικη αγωγη διαφορων διαταραχων | |
ATE373719T1 (de) | Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung | |
ATE361100T1 (de) | Methode zur krebs-behandlung mit anti- neurotrophin mittel | |
ATE378403T1 (de) | Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern | |
DK1434791T3 (da) | Specifikke bindingsmidler til human angiopoietin-2 | |
ATE369380T1 (de) | Impfstoff zur verhütung und behanldung von alzheimer-demenz und von amyloid-bezogenen krankheiten | |
BRPI0418745A (pt) | anticorpo linhagem de células, composição farmacêutica, e, método de tratamento de cáncer em um paciente | |
HUP9802212A2 (hu) | Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok | |
ATE390480T1 (de) | Transplant-akzeptanz induzierende zellen monocytären ursprungs, sowie deren herstellung und verwendung | |
DK1411962T3 (da) | Terapi for pancreacancer med monoklonalt stof | |
ATE525480T1 (de) | Verwendung von a33-antigenen und jam-it | |
WO2004030607A3 (en) | Peptide-based passive immunization therapy for treatment of atherosclerosis | |
ATE314861T1 (de) | Verwendung von antikörper gegen mag zur behandlung ischämischer schlaganfälle | |
DE60042489D1 (de) | Impfstoff gegen neisseria infektion | |
SE0202959D0 (sv) | Peptide-Base passive immunization therapy for treatment of atherosclerosis |